Global Prescription Drugmakers

Established prescription-drug franchises offer exposure to medical demand rather than AI infrastructure spending as technology shares reset. Amgen's upcoming earnings provide a near-term test of commercial execution, while the basket spreads patent and clinical-development risk across distinct drug portfolios. Recent healthcare strength supports the theme, but pricing pressure and pipeline disappointments remain material risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, GILD, PFE Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.